Explore the words cloud of the STriTuVaD project. It provides you a very rough idea of what is the project "STriTuVaD" about.
The following table provides information about the project.
ETNA BIOTECH SRL
|Coordinator Country||Italy [IT]|
|Total cost||5˙050˙656 €|
|EC max contribution||4˙549˙527 € (90%)|
1. H2020-EU.3.1.5. (Methods and data)
|Duration (year-month-day)||from 2018-02-01 to 2022-07-31|
Take a look of project's partnership.
|1||ETNA BIOTECH SRL||IT (CATANIA)||coordinator||1˙043˙750.00|
|2||INFECTIOUS DISEASE RESEARCH INSTITUTE||US (SEATTLE WA)||participant||1˙255˙027.00|
|3||UNIVERSITA DEGLI STUDI DI CATANIA||IT (CATANIA)||participant||909˙393.00|
|4||THE UNIVERSITY OF SHEFFIELD||UK (SHEFFIELD)||participant||465˙323.00|
|5||ARCHIVEL FARMA, SL||ES (BADALONA)||participant||408˙360.00|
|6||ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA||IT (BOLOGNA)||participant||402˙047.00|
|7||STICHTING TUBERCULOSIS VACCINE INITIATIVE||NL (LELYSTAD)||participant||65˙625.00|
|8||THE ALL-INDIA INSTITUTE OF MEDICAL SCIENCES||IN (NEW DELHI)||participant||0.00|
Tuberculosis (TB) one of the world’s deadliest diseases: one third of the world’s population, mostly in developing countries, is infected with TB. But TB is becoming again very dangerous also for developed countries, due to the increased mobility of the world population, and the appearance of several new bacterial strains that are multi-drug resistant (MDR). There is now a growing awareness that TB can be effectively fought only working globally, starting from countries like India, where the infection is endemic. Once a person present the active disease, the most critical issue is the current duration of the therapy, because of the high costs it involved, the increased chances of non-compliance (which increase the probability of developing an MDR strain), and the time the patient is still infectious to others. One exciting possibility to shorten the duration of the therapy are new host-reaction therapies (HRT) as a coadjuvant of the antibiotic therapy. The endpoints in the clinical trials for HRTs are time to inactivation, and incidence of recurrence. While for the first it is in some cases possible to have a statistically powered evidence for efficacy in a phase II clinical trial, recurrence almost always require a phase III clinical trial with thousands of patients involved, and huge costs. In the STriTuVaD project we will extend our Universal Immune System Simulator to include all relevant determinants of such clinical trial, establish its predictive accuracy against the individual patients recruited in the trial, use it to generate virtual patients and predict their response to the HRT being tested, and combine them to the observations made on physical patients using a new in silico-augmented clinical trial approach that uses a Bayesian adaptive design. This approach, where found effective could drastically reduce the cost of innovation in this critical sector of public healthcare.
|Report on the extensions implemented into the modeling simulation platform to reproduce the immune system â€“ TBC â€“ vaccines interactions and dynamics||Documents, reports||2020-04-16 10:07:03|
|Report on the creation of the subjects-specific and virtual patients libraries that will be used in the implementation of the in silico clinical trial||Documents, reports||2020-04-16 10:07:03|
|Governance and meetings: the governance bodies are set. SC meetings organised: logistic, preparation of programme, invitation of experts||Documents, reports||2020-04-16 10:07:03|
|Report on the data collection and selection on TB disease and candidate vaccines/treatments||Documents, reports||2020-04-16 10:07:03|
|First dissemination report||Documents, reports||2020-04-16 10:07:03|
|Public web site||Websites, patent fillings, videos etc.||2020-04-16 10:07:03|
|A coherent hierarchical Bayesian model encompassing the virtual and real data sources.||Documents, reports||2020-04-16 10:07:03|
|Report on the modeling simulation framework able to simulate human immune system dynamics||Documents, reports||2020-04-16 10:07:03|
|Dissemination plan||Documents, reports||2020-04-16 10:07:03|
Take a look to the deliverables list in detail: detailed list of STriTuVaD deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRITUVAD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "STRITUVAD" are provided by the European Opendata Portal: CORDIS opendata.
A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized healthRead More
Integrated and standardized NGS workflows for Personalised therapyRead More
EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.Read More